ForsLean® is Sabinsa's new proprietary composition extract of Coleus forskohlii root, standardized for 10 percent forskohlin.
ForsLean® has shown promising results in three areas; enhancing lean body mass, promoting fat loss and promoting weight loss.
In September of 1998 Sabinsa was granted a use patent for this application of forskohlin in its ForsLean® composition.
The importance of maintaining or regaining lean body mass has recently come to light for two important reasons. First
is the increased recognition that lean body mass plays a vital role in any successful weight training regimen, and second,
there is a growing awareness that lean body mass is proportionate to the overall health of an individual.
Lean body mass is composed of muscle, vital organs, bone and bone marrow, connective tissue and body water. The percentage
of lean body mass to fat not only determines the body's aesthetic appearance, but more importantly, it is also an index of
physical fitness, health status, susceptibility to disease and premature mortality. Because the body's metabolic rate is directly
proportional to the amount of lean body mass, there is substantial interest in products that safely increase lean body mass
because they are most likely to work. The use of ForsLean® may help to increase lean body mass and optimize body composition
with one of the side effects being fat loss and/or weight loss.
A sluggish metabolic rate is an undesired effect of many weight-loss regimens. It was observed in one study that formerly
obese subjects had a 3-5% lower resting metabolic rate than control subjects. The occurrence of a low resting metabolic rate
is likely to contribute to the high rate of weight regain in formerly obese persons.
Clearly, we need to change and broaden our thinking on the objectives of weight management regimens for both active and
not-so-active individuals. In particular, it should be emphasized that healthy functioning of the body depends not so much
on a lower fat content, but rather on obtaining a higher percentage of lean body mass. Again, it should be kept in mind that
it is not only fat, but also lean body mass that is, or can be, lost through dieting. This fact often escapes our attention
when we reduce our total body weight. The loss of lean body mass offsets any benefits derived from the reduction of body weight,
and can potentially increase one's chances for diabetes, cardiovascular disease and possibly some forms of cancer due to poor
Mechanism of Action
"ForsLean® shifts the proportion between lean body mass and adipose, or fatty, tissue in favor of lean body mass,
which improves overall health," explains Vladimir Badmaev, MD, PhD, Sabinsa Corporation's Vice President, Scientific
and Medical Affairs. "The effect can be measured by decreases in the waist hip ratio and the body mass index."
The mechanism of action on how ForsLean® works is well defined. Badmaev adds, "Forskohlin, the active compound in
ForsLean®, is recognized as an adenylate cyclase activator. Adenylate cyclase is the enzyme involved in the production of
cyclic adenosine monophosphate (cAMP), a significant biochemical agent in metabolic processes. The role of cyclic AMP is indispensable
to many body functions. It induces a chain reaction of biochemical events that trigger metabolic processes and diet induced
thermogenesis, thereby providing the means to maintain healthy body composition and lean body mass levels."
Proof of Efficacy Summary
ForsLean® was tested in an open-field study with a population of six overweight women (BMI>25). The tested formula
was in the form of two-piece, hard shell capsules; each capsule contained 250 mg of ForsLean®. The overweight, but otherwise
healthy women, received one capsule twice daily for eight weeks. Participants were instructed to take one capsule in the morning
and one in the evening, half an hour before a meal. Each participant was asked to maintain her previous daily physical exercise
and eating habits. In addition, physical activity was monitored based on a questionnaire before and during the trial.
During the eight week trial, the mean values for body weight and fat content significantly decreased, whereas lean body
mass was significantly increased as compared to the baseline. Neither the systolic/diastolic blood pressure, nor the pulse
rate was adversely affect during the trial. Indeed, a trend was observed of lower systolic/diastolic pressure during the course